HD DECA 250

COMPOSITION 

Each ml contains: 

Nandrolone Decanoate 250 mg 

Oil Base q.s.  

PHARMACOLOGICAL CLASSIFICATION 

Anabolic Steroids  

PHARMACOLOGICALACTION 

Deca 250 is an injectable anabolic preparation. After injection, Nandrolone Decanoate is  gradually released from the intramuscular depot and subsequently hydrolysed into nandrolone. 

INDICATIONS 

As an anabolic steroid.  

Certain cases of disseminated breast cancer in women. 

Osteoporosis due to androgen deficiency in hypogonadal males.  

CONTRA-INDICATIONS 

Not intended for use in children. 

Known or suspected prostatic carcinoma and mammary carcinoma in the male. Not intended for use in female patients other than those with disseminated breast cancer. Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure,  hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and  hepatic carcinoma. 

DOSAGE AND DIRECTIONS FOR USE 

Deca 250 should be administered by deep intramuscular injection. 

SIDE-EFFECTS AND SPECIAL PRECAUTIONS 

Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased  libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in  girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom  of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. 

Other adverse reactions may include: 

-Oligospermia and decreased ejaculatory volume; 

-Suppression of ovarian activity, atrophy of the breasts and endometrial tissue. -Amenorrhoea and inhibition of spermatogenesis. 

-Water and salt retention. 

-Premature epiphyseal closure. 

-If signs of virilisation develop, treatment should be discontinued. 

-Increase in nitrogen retention and skeletal weight; 

-Oedema; 

-Increased vascularity of the skin; 

-Increased growth of the bone; 

-Elderly males may become over-stimulated. 

Patients with the following conditions should be monitored: 

Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of  these conditions), since anabolic steroids may induce salt and fluid retention; diabetes, since  anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other  antidiabetic dugs; incomple testatural growth, since anabolic steroids in high dosages may accelerate  epiphyseal closure; skeletal metastases, since anabolic steroids may induce hypercalcaemia and  hypercalciuria in these patients. 

Interactions: 

Liver-enzyme-inducing agents may reduce the effects of Deca 250 by enhancing its metabolism  in the liver. 

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT See "Side-effects and special precautions". Treatment is symptomatic and supportive. 

STORAGE INSTRUCTIONS : 

Store at room temperature below 30° C. 

Protect from light  

Keep drugs out of children's reach